Result Filters
Adverse events associated with COVID-19 pharmaceutical treatments
- Author(s):
- Maglione, Margaret, author
- Title(s):
- Adverse events associated with COVID-19 pharmaceutical treatments / Margaret Maglione, Jeffrey D. Klausner, Patricia K. Wirnkar, Ivan Fallarme, Rozhin Lak, Kimny Sysawang, Ning Fu, Sachi Yagyu, Aneesa Motala, Danica Tolentino, Susanne Hempel.
- Series:
- Rapid evidence product
Report ; no. 24-EHC011
- Country of Publication:
- United States
- Publisher:
- Rockville (MD) : Agency for Healthcare Research and Quality (US), 2024.
- Description:
- 1 online resource (1 PDF file (41, C-70 pages)) : illustrations.
-
Language:
- English
- Electronic Links:
- https://www.ncbi.nlm.nih.gov/books/NBK601979/
- Summary:
- The purpose of this rapid review is to determine if COVID treatments authorized for emergency use by the Food and Drug Administration (FDA) are associated with serious harms. The review will be used by the Health Resources & Services Administration (HRSA) Countermeasures Injury Compensation Program to inform a Countermeasures Injury Table (Table). Once a Table and any relevant amendments are published, the Table will be used to make benefits eligibility determinations for covered injuries or deaths. The Agency for Healthcare Research and Quality (AHRQ) commissioned this rapid review using abbreviated methods to provide an assessment of evidence in a compressed timeframe to inform HRSA’s work. The following pharmaceutical interventions to treat or prevent COVID-19 were reviewed: Convalescent plasma (from recovered COVID-19 patients); Antivirals: Remdesivir (Veklury), Nirmatrelvir and Ritonavir in combination (Paxlovid), Molnupiravir (Lagevrio); Monoclonal antibodies: Bamlanivimab and Etesevimab in combination, Bebtelovimab, Casirivimab and Imdevimab in combination (Regeneron), Sotrovimab (Xevudy), Tixagevimab and Cilgavimab in combination (Evusheld), Tocilizumab (Actemra); Interleukin-1 receptor antagonist: Anakinra (Kineret).
- MeSH:
- Antibodies, Monoclonal/adverse effects
Antiviral Agents/adverse effects
COVID-19 Drug Treatment.*
COVID-19 Serotherapy/adverse effects
Drug-Related Side Effects and Adverse Reactions
- Publication Type(s):
- Review
- Notes:
- Caption title.
- Other ID:
- (OCoLC)1432352439
- NLM ID:
- 9918802922006676 [Electronic Resource]